Andere talen LigaChem Biosciences Inc.

Aandelen

A141080

KR7141080002

slotkoers Korea S.E. Andere beurzen 00:00:00 28-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
71.200 ^KRW	-0,84%		-1,79%	+9,54%

16/05	LigaChem Biosciences Inc. rapporteert resultaten voor het eerste kwartaal dat eindigde op 31 maart 2024	CI
08/04	NextCure, Inc. en LigaChem Biosciences, Inc. presenteren preklinische gegevens over B7-H4 antilichaam geneesmiddelconjugaat op AACR 2024	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

LigaChem Biosciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	16/05
NextCure, Inc. and LigaChem Biosciences, Inc. Present Preclinical Data on B7-H4 Antibody Drug Conjugate At AACR 2024	08/04
Pan Orion Corp. Ltd. completed the acquisition of 4.93% stake in LegoChem Biosciences, Inc. from Kim Yong Ju and Park Se Jin.	29/03
LigaChem Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03
Samsung Biologics Collaborates with LegoChem Biosciences on ADC Development and Manufacturing	09/02
Samsung Biologics partners with LegoChem Biosciences for ADC development and manufacturing	08/02
Orion Set to Acquire 25% Stake in LegoChem Biosciences	17/01
South Korean Shares Close Lower Amid Geopolitical Tension	16/01
Legochem Biosciences to Raise 469.8 Billion Won through Rights Issue; Shares Fall 5%	16/01
LegoChem Biosciences, Inc. announced that it expects to receive KRW 1018.327793998 billion in funding from Pan Orion Corp. Ltd.	15/01
Tranche Update on LegoChem Biosciences, Inc.'s Equity Buyback Plan announced on June 28, 2023.	28/12
LegoChem Biosciences, Inc.'s Equity Buyback announced on June 28, 2023, has expired with 140,000 shares, representing 0.53% for KRW 4,879.08 million.	28/12
J&J : accord de licence avec le coréen LegoChem dans les ADC	27/12
Legochem Biosciences Announces License Agreement for Lcb84 Trop2-Targeted ADC	26/12
A little bit bad feels good	28/11
LegoChem Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
LegoChem Biosciences Selects BostonGene as Genomic Partner for First-in-Human Clinical Trial	08/11
BostonGene and LegoChem Biosciences, Inc. Announce Collaboration to Support Phase I/II Study of LCB84, TROP2-Directed ADC, in Patients with Advanced Cancers	07/11
Tranche Update on LegoChem Biosciences, Inc.'s Equity Buyback Plan announced on June 28, 2023.	04-10-23
Tranche Update on LegoChem Biosciences, Inc.'s Equity Buyback Plan announced on June 28, 2023.	04-10-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen LigaChem Biosciences Inc.

Aandelen

A141080

KR7141080002

Andere talen

Filters